Ren Xiaoli, Fan Yuying, Li Yongqi, Shi Dongmei, Liu Yun
College of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou, Henan 450046, PR China.
Department of Veterinary Clinic, College of Veterinary Medicine, Northeast Agricultural University, Harbin, Heilongjiang 150000, PR China.
J Vet Res. 2022 Jul 5;66(2):267-272. doi: 10.2478/jvetres-2022-0033. eCollection 2022 Jun.
Enhancer of zeste homologue 2 (EZH2) is the human homologue of gene enhancer. The aim of this study was to determine the expression of EZH2 in canine mammary carcinomas (CMCs) and its relationship with clinicopathological features.
The expression of EZH2 mRNA and protein in 53 CMC tissue and 8 normal mammary gland tissue samples was measured by quantitative real-time PCR and immunohistochemical staining assay, respectively. The relationship between EZH2 protein expression and clinicopathological features was analysed by χ2 test to further explore the clinical significance of EZH2 in CMCs.
Compared with normal mammary gland tissues, EZH2 mRNA expressions were significantly increased in CMC tissues (P < 0.01). Moreover, normal mammary glands did not express the EZH2 protein but carcinomic glands did, and expression increased in CMCs with high histological grades, especially in histological grade II (P < 0.05). However, EZH2 expression was not related to age, tumour size, or metastasis (P > 0.05). The expression of EZH2 in one type of CMC was not significantly different from the expression in any other type (P > 0.05).
EZH2 is highly expressed in CMCs, indicating that it can be used as a molecular marker for early diagnosis, prognosis, or therapy of CMCs.
zeste 同源物 2 增强子（EZH2）是基因增强子的人类同源物。本研究旨在确定 EZH2 在犬乳腺癌（CMC）中的表达及其与临床病理特征的关系。
分别采用定量实时 PCR 和免疫组织化学染色法检测 53 例 CMC 组织和 8 例正常乳腺组织样本中 EZH2 mRNA 和蛋白的表达。采用 χ2 检验分析 EZH2 蛋白表达与临床病理特征之间的关系，以进一步探讨 EZH2 在 CMC 中的临床意义。
与正常乳腺组织相比，CMC 组织中 EZH2 mRNA 表达显著增加（P < 0.01）。此外，正常乳腺组织不表达 EZH2 蛋白，而癌组织表达，且在高组织学分级的 CMC 中表达增加，尤其是在组织学二级（P < 0.05）。然而，EZH2 表达与年龄、肿瘤大小或转移无关（P > 0.05）。EZH2 在一种类型的 CMC 中的表达与在任何其他类型中的表达无显著差异（P > 0.05）。
EZH2 在 CMC 中高表达，表明它可作为 CMC 早期诊断、预后或治疗的分子标志物。
